Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
Active, not recruiting · NCT03422393 · Registry updated 2024-07-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Disease Progression, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 | 2024-07-05 | NCT03422393 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Michael Choi | 1 |
| Pharmacyclics LLC. | 12 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | United States | 199 |